No Data
Baicheng Pharmaceutical (301096.SZ): Currently, the company has 6 projects in the research and development of biopharmaceuticals.
Gelonghui on November 6th: Baicheng Pharmaceutical (301096.SZ) stated on the investor interaction platform that the company is a comprehensive pharmaceutical R&D enterprise with technology development as the core, integrating innovation, full value chain, platformization, and inclusive attributes. It mainly provides CRO services, research and development technology transformation services, and customized research and development production services (CDMO) for various pharmaceutical companies and pharmaceutical R&D investment enterprises. Currently, the company has 6 projects in the research and development of large molecule biopharmaceuticals.
Baicheng Pharmaceuticals (301096.SZ): Currently, there is sufficient order backlog, and the operation is normal.
Glory Union reported on November 6th that Baicheng Pharmaceuticals (301096.SZ) stated on the investor interaction platform that the company currently has sufficient orders on hand, and the operation is normal.
Baicheng Pharmaceutical (301096): Q3 performance under temporary pressure, self-developed technology transformation helps drive business transformation.
In Q3, the performance is under pressure in stages, with the overall growth rate of new signed orders in the first half of the year remaining steady. In 2024 Q1-3, the company achieved revenue of 0.721 billion yuan, a year-on-year increase of 1.07%; net income attributable to the parent company was 0.142 billion yuan, a year-on-year decline of 29.69%.
A-share abnormal movement ︱ Baicheng Medicine fell more than 8%, with increased revenue in the first three quarters but no increase in profit.
Galaxy News on October 29th: CRO concept stocks fluctuated downward, among which Baicheng Medicine (301096.SZ) fell by more than 8%, closing at 41.25 yuan, with a total market value of 4.5 billion yuan. The company announced after hours yesterday that the revenue in the first three quarters was 0.721 billion yuan, a year-on-year increase of 1.07%; net income attributable to shareholders of listed companies was 0.142 billion yuan, a year-on-year decrease of 29.69%. It is reported that the company currently has subsidiaries in Macau, China, with several projects registered and implemented. Three active pharmaceutical ingredients have successfully applied for EU CEP acceptance in 2024. (Galaxy News)
Concept stocks related to contract research organizations (CRO) in the A-share market are fluctuating and trending lower, with Haoyuan Pharmaceuticals falling more than 10%.
On October 29th, Galonghui reported that Haoyuan Pharmaceutical fell by more than 10%, with Baicheng Pharmaceutical, Nuosige, qingdao vland biotech inc., Sunshine Noru and shanghai medicilon inc. leading the decline.
Baicheng Pharmaceutical: Report for the third quarter of 2024
No Data
No Data